


CDK9-IN-7

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-126251 | | |
| CAS No.: | 2369981-71-3 | | |
| Molecular Formula: | C ₂₉ H ₃₇ N ₇ O ₂ S | | |
| Molecular Weight: | 547.71 | | |
| Target: | CDK; Apoptosis | | |
| Pathway: | Cell Cycle/DNA Damage; Apoptosis | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

| | | | | |
|---|---|--------------------------|-----------|------------|
| In Vitro | DMSO : 62.5 mg/mL (114.11 mM; Need ultrasonic) | | | |
| | | Solvent Concentration | Mass | |
| | | | 1 mg | 5 mg |
| | | | 10 mg | |
| Preparing Stock Solutions | 1 mM | 1.8258 mL | 9.1289 mL | 18.2578 mL |
| | 5 mM | 0.3652 mL | 1.8258 mL | 3.6516 mL |
| | 10 mM | 0.1826 mL | 0.9129 mL | 1.8258 mL |
| Please refer to the solubility information to select the appropriate solvent. | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution | | | |

BIOLOGICAL ACTIVITY

| | | | |
|-------------------------------------|---|---|--|
| Description | CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC ₅₀ =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC ^[1] . | | |
| IC₅₀ & Target | CDK9/cyclinT1 11 nM (IC ₅₀) | CDK4/cyclin D 148 nM (IC ₅₀) | CDK6/cyclinD 145 nM (IC ₅₀) |
| In Vitro | CDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC ₅₀ values less than 0.5 μM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC ₅₀ value of 0.837 μM ^[1] | | |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA